HomeVesalius Cardiovascular Inc.

Vesalius Cardiovascular Inc.

Vesalius Cardiovascular Reaches a New and Advanced Pre-Clinical Milestone

Vesalius Cardiovascular Inc. notes the predetermined endpoints of the study were the feasibility and durability of VCI's papillary muscle anchoring device. Both endpoints were confirmed at the 180-day mark.

Vesalius Cardiovascular Announces the Completion of a Successful Chronic Animal Study

The predetermined endpoints of the study were the absence of device or valve thrombosis and the absence of leaflet injury due to the device, and both endpoints were robustly confirmed upon completion of the study.